IDSA recommends shorter antibiotic courses for adults with cUTIs who show clinical improvement on effective therapy.

The Food and Drug Administration (FDA) has granted Qualified Disease Product and Fast Track designation to NRX-101 for the treatment of complicated urinary tract infection (cUTI) and pyelonephritis.

Exblifep is a combination product that consists of cefepime, a cephalosporin antibacterial, and enmetazobactam, a beta-lactamase inhibitor. The Food and Drug Administration (FDA) has approved Exblifep ...

Wockhardt announced that its novel intravenous antibiotic Foviscu (WCK 4282) has successfully met the primary endpoint in a Phase 3 clinical trial in patients with complicated urinary tract infections ...

RADNOR, Pa., Jan. 16, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company ...

Cefepime-taniborbactam was 22% more effective than meropenem, which is a current treatment for complicated urinary tract infections (UTIs) and acute pyelonephritis, according to a study published in ...

Compared with meropenem, cefepime-taniborbactam is superior for microbiologic and clinical cure of complicated urinary tract infection, including acute pyelonephritis. Cefepime-taniborbactam is more ...

March is National Kidney Month, a time to raise awareness about your kidney health and generate support for those affected by conditions, including kidney stones, kidney infections and kidney disease.

Researchers from Shaanxi Panlong Pharmaceutical Group Co. Ltd., Shaanxi Pioneer Biotech Co. Ltd. and affiliated organizations presented the discovery and preclinical characterization of novel ...

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation ...